The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Anti-inflammatory therapeutics for the treatment of atherosclerosis
Open accessAbstract
Atherosclerosis is the primary cause of heart disease and stroke and is thus the underlying pathology of the leading causes of death in the western world. Although risk can be reduced by lowering lipid levels, the equally important contribution of inflammation to the development of cardiovascular disease is not adequately addressed by existing therapies. Here, we summarize the evidence supporting a role for inflammation in the pathogenesis of atherosclerosis, discuss agents that are currently in the clinic and provide a perspective on the challenges faced in the development of drugs that target vascular inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,839
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,736
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292 · cited 1×
“Among the soluble markers that have been studied, the marker that is most reproducibly associated with cardiovascular risk is C-reactive protein (CRP) or high-sensitivity CRP (hsCRP), which has been established both as an inflammatory biomarker and as a risk factor for cardiovascular diseas”
BackgroundInflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965
Self-citationSerbina, N. V., & Pamer, E. G. (2006) · Nature Immunology · doi:10.1038/ni1309 · Cited by 1,669
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E. (1999) · Circulation · doi:10.1161/01.cir.100.3.230 · Cited by 1,478
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Nissen, S. E., Tuzcu, E. M., Libby, P., Thompson, P. D., Ghali, M., Garza, D., Berman, L., Shi, H., Buebendorf, E., Topol, E. J., et al. (2004) · JAMA · doi:10.1001/jama.292.18.2217 · Cited by 1,154
Tsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., & Charo, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29919 · Cited by 1,152
Self-citationSwirski, F. K., Libby, P., Aikawa, E., Alcaide, P., Luscinskas, F. W., Weissleder, R., & Pittet, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29950 · Cited by 1,148
Cushing, S. D., Berliner, J. A., Valente, A. J., Territo, M. C., Navab, M., Parhami, F., Gerrity, R., Schwartz, C. J., & Fogelman, A. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5134 · Cited by 1,146
Peters-Golden, M., & Henderson, W. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071371 · Cited by 1,013
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke
Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., Samani, N. J., Gudmundsson, G., Grant, S. F. A., Thorgeirsson, G., et al. (2004) · Nature Genetics · doi:10.1038/ng1311 · Cited by 927
Monocyte chemoattractant protein-1 in human atheromatous plaques.
Nelken, N. A., Coughlin, S. R., Gordon, D., & Wilcox, J. N. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115411 · Cited by 880
Genetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Ridker, P. M., Rifai, N., & Clearfield, M. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00460-3 · Cited by 760
Charo, I. F., Myers, S. J., Herman, A., Franci, C., Connolly, A. J., & Coughlin, S. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2752 · Cited by 705
Self-citationHyperlipidemia-triggered neutrophilia promotes early atherosclerosis
Drechsler, M., Megens, R. T. A., van Zandvoort, M., Weber, C., & Soehnlein, O. (2010) · Circulation · doi:10.1161/circulationaha.110.961714 · Cited by 698
Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis
Dwyer, J. H., Allayee, H., Dwyer, K. M., Fan, J., Wu, H., Mar, R., Lusis, A. J., & Mehrabian, M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa025079 · Cited by 619
Aikawa, M., Rabkin, E., Sugiyama, S., Voglic, S. J., Fukumoto, Y., Furukawa, Y., Shiomi, M., Schoen, F. J., & Libby, P. (2001) · Circulation · doi:10.1161/01.cir.103.2.276 · Cited by 588
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives -
Zhou, Q., & Liao, J. K. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0110 · Cited by 567
Drazen, J. M., Yandava, C. N., Dubé, L., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N., Silverman, E. S., Katz, D. A., et al. (1999) · Nature Genetics · doi:10.1038/9680 · Cited by 560
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Jacobsson, L., Turesson, C., Gülfe, A., Kapetanovic, M. C., Petersson, I. F., Saxne, T., & Geborek, P. (2005) · PubMed · Cited by 533
Solinas, G., Vilcu, C., Neels, J. G., Bandyopadhyay, G. K., Luo, J.-L., Naugler, W., Grivennikov, S., Wynshaw-Boris, A., Scadeng, M., Olefsky, J. M., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.011 · Cited by 513
Serruys, P. W., García-García, H. M., Buszman, P., Erne, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, O., Dudek, D., Bøtker, H. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.771899 · Cited by 505
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 498
Spanbroek, R., Gräbner, R., Lötzer, K., Hildner, M., Urbach, A., Rühling, K., Moos, M. P. W., Kaiser, B., Cohnert, T. U., Wahlers, T., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242716099 · Cited by 458
Koenen, R. R., von Hundelshausen, P., Nesmelova, I. V., Zernecke, A., Liehn, E. A., Sarabi, A., Kramp, B. K., Piccinini, A. M., Paludan, S. R., Kowalska, M. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1898 · Cited by 440
Wilensky, R. L., Shi, Y., Mohler, E. R., Hamamdzic, D., Burgert, M. E., Li, J., Postle, A., Fenning, R. S., Bollinger, J. G., Hoffman, B. E., et al. (2008) · Nature Medicine · doi:10.1038/nm.1870 · Cited by 387
Chemokines in Atherosclerosis: An Update
Zernecke, A., Shagdarsuren, E., & Weber, C. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.161174 · Cited by 376
Blankenberg, S., Zeller, T., Saarela, O., Havulinna, A. S., Kee, F., Tunstall-Pedoe, H., Kuulasmaa, K., Yarnell, J., Schnabel, R. B., Wild, P. S., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.901413 · Cited by 367
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm
Zhao, L., Moos, M. P. W., Gräbner, R., Pédrono, F., Fan, J., Kaiser, B., John, N., Schmidt, S., Spanbroek, R., Lötzer, K., et al. (2004) · Nature Medicine · doi:10.1038/nm1099 · Cited by 354
Leukotriene modifiers as potential therapeutics for cardiovascular disease
Funk, C. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1796 · Cited by 326
RIDKER, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 270
Inflammation and Cardiovascular Disease: Role of the Interleukin-1 Receptor Antagonist
Fearon, W. F., & Fearon, D. T. (2008) · Circulation · doi:10.1161/circulationaha.108.772491 · Cited by 241
Yvan-Charvet, L., Kling, J., Pagler, T., Li, H., Hubbard, B., Fisher, T., Sparrow, C. P., Taggart, A. K., & Tall, A. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207142 · Cited by 240
Hakonarson, H., Thorvaldsson, S., Helgadottir, A., Gudbjartsson, D., Zink, F., Andresdottir, M., Manolescu, A., Arnar, D. O., Andersen, K., Sigurdsson, A., et al. (2005) · JAMA · doi:10.1001/jama.293.18.2245 · Cited by 236
Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?
Schindhelm, R. K., van der Zwan, L. P., Teerlink, T., & Scheffer, P. G. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.126029 · Cited by 234
Helgadottir, A., Gretarsdottir, S., St. Clair, D., Manolescu, A., Cheung, J., Thorleifsson, G., Pasdar, A., Grant, S. F. A., Whalley, L. J., Hakonarson, H., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/428066 · Cited by 232
Popa, C., Netea, M. G., Radstake, T., Van der Meer, J. W. M., Stalenhoef, A. F. H., van Riel, P. L. C. M., & Barerra, P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.023119 · Cited by 224
Yu, X., Dluz, S., Graves, D. T., Zhang, L., Antoniades, H. N., Hollander, W., Prusty, S., Valente, A. J., Schwartz, C. J., & Sonenshein, G. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6953 · Cited by 220
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Lindå, H., von Heijne, A., Major, E. O., Ryschkewitsch, C., Berg, J., Olsson, T., & Martin, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810316 · Cited by 218
Tardif, J.-C., McMurray, J. J., Klug, E., Small, R., Schumi, J., Choi, J., Cooper, J., Scott, R., Lewis, E. F., L'Allier, P. L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60763-1 · Cited by 199
Gilbert, J., Lekstrom-Himes, J., Donaldson, D., Lee, Y., Hu, M., Xu, J., Wyant, T., & Davidson, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.005 · Cited by 185
From Asthma to Atherosclerosis — 5-Lipoxygenase, Leukotrienes, and Inflammation
De Caterina, R., & Zampolli, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp038190 · Cited by 175
Association Between 5-Lipoxygenase Expression and Plaque Instability in Humans
Cipollone, F., Mezzetti, A., Fazia, M. L., Cuccurullo, C., Iezzi, A., Ucchino, S., Spigonardo, F., Bucci, M., Cuccurullo, F., Prescott, S. M., et al. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000172632.96987.2d · Cited by 173
Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies
Klingenberg, R., & Hansson, G. K. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp477 · Cited by 169
Vascular Biomarkers and Surrogates in Cardiovascular Disease
Tardif, J.-C., Heinonen, T., Orloff, D., & Libby, P. (2006) · Circulation · doi:10.1161/circulationaha.105.598987 · Cited by 163
Tardif, J., L’Allier, P. L., Ibrahim, R., Grégoire, J. C., Nozza, A., Cossette, M., Kouz, S., Lavoie, M.-A., Paquin, J., Brotz, T. M., et al. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.110.937169 · Cited by 161
Self-citationLeukotriene Signaling in Atherosclerosis and Ischemia
Bäck, M. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6140-9 · Cited by 134
White, H. D., Held, C., Stewart, R., Watson, D. I., Harrington, R. A., Budaj, A., Steg, P. G., Cannon, C. P., Krug‐Gourley, S., Wittes, J. T., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.006 · Cited by 125
Part 9: Acute Coronary Syndromes
O’Connor, R. E., Bossaert, L. L., Arntz, H.-R., Brooks, S. C., Diercks, D., Feitosa-Filho, G. S., Nolan, J. P., Hoek, T. L. V., Walters, D., Wong, A., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.985549 · Cited by 121
5-Lipoxygenase and atherosclerosis
Mehrabian, M., & Allayee, H. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00005 · Cited by 118
The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis
LOTZER, K., FUNK, C., & HABENICHT, A. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.07.001 · Cited by 108
Barlic, J., Zhang, Y., Foley, J. F., & Murphy, P. M. (2006) · Circulation · doi:10.1161/circulationaha.105.602359 · Cited by 94
Reifenberg, K., Lehr, H., Baskal, D., Wiese, E., Schaefer, S. C., Black, S., Samols, D. R., Torzewski, M., Lackner, K. J., Husmann, M., et al. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000171983.95612.90 · Cited by 92
Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells
Zapolska‐Downar, D., Siennicka, A., Kaczmarczyk, M., Kołodziej, B., & Naruszewicz, M. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.03.005 · Cited by 86
Crossman, D. C., Morton, A. C., Gunn, J. P., Greenwood, J. P., Hall, A. S., Fox, K. A. A., Lucking, A. J., Flather, M. D., Lees, B., & Foley, C. E. (2008) · Trials · doi:10.1186/1745-6215-9-8 · Cited by 81
Tabibiazar, R., Wagner, R. A., Ashley, E. A., King, J. Y., Ferrara, R., Spin, J. M., Sanan, D. A., Narasimhan, B., Tibshirani, R. J., Tsao, P. S., et al. (2005) · Physiological Genomics · doi:10.1152/physiolgenomics.00001.2005 · Cited by 77
Rosenson, R. S. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6148-1 · Cited by 71
Rosenson, R. S., Elliott, M. D., Stasiv, Y., Hislop, C., for the PLASMA II Investigators, Imburgia, M., Weiss, R., Underwood, P., Ende, D. J., Brown, C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq374 · Cited by 66
Shaposhnik, Z., Wang, X., Trias, J., Fraser, H. I., & Lusis, A. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800361-jlr200 · Cited by 64
Hartford, M., Wiklund, O., Hultén, L. M., Perers, E., Person, A., Herlitz, J. D., Hurt‐Camejo, E., Karlsson, T., & Caidahl, K. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.04.004 · Cited by 62
Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease
Assimes, T. L., Knowles, J. W., Priest, J. R., Basu, A., Volcik, K. A., Southwick, A. M., Tabor, H. K., Hartiala, J., Allayee, H., Grove, M. L., et al. (2008) · Human Genetics · doi:10.1007/s00439-008-0489-5 · Cited by 61
Targeting Adhesion Molecules in Cardiovascular Disorders
Haverslag, R. T., Pasterkamp, G., & Hoefer, I. E. (2008) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152908786786188 · Cited by 58
Anti-inflammatory Properties of Statins
Steffens, S., & Mach, F. (2004) · Seminars in Vascular Medicine · doi:10.1055/s-2004-869599 · Cited by 49
Aiello, R. J., Perry, B. D., Bourassa, P.-A. K., Robertson, A. W., Weng, W., Knight, D. R., Smith, A. H., Frederick, K. S., Kalgutkar, A. S. S., & Gladue, R. P. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.017 · Cited by 46
Rationally Evolving MCP-1/CCL2 into a Decoy Protein with Potent Anti-inflammatory Activity in Vivo
Piccinini, A. M., Knebl, K., Rek, A., Wildner, G., Diedrichs‐Möhring, M., & Kungl, A. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.043299 · Cited by 42
Phospholipase A2s: Developing drug targets for atherosclerosis
Suckling, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.03.011 · Cited by 29
The role of cardiac troponin in the recent redefinition of acute myocardial infarction.
Wu, A. H. B. (2004) · PubMed · Cited by 12
Cardiovascular Molecular Imaging
Fayad, Z. A. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.191809 · Cited by 9
Cited by
Multiple Roles for Neutrophils in Atherosclerosis
Soehnlein, O. (2012) · Circulation Research · doi:10.1161/circresaha.111.257535 · Cited by 498
Perspectives and opportunities for nanomedicine in the management of atherosclerosis
Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423
Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08791-9 · Cited by 382
“Importantly, statins exert anti-inflammatory effects on several cells that are involved in the development and rupture of atherosclerotic plaques [112, 113].”
BackgroundMechanisms of thrombosis in obesity
Blokhin, I. O., & Lentz, S. R. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283634443 · Cited by 345
van Diepen, J. A., Berbée, J. F. P., Havekes, L. M., & Rensen, P. C. N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.028 · Cited by 292
Metadata
- Authors
- Charo, I. F., & Taub, R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 365-376
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2083200530
- Cited by
- 306
- References
- 88
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.